Skip to content

US · INSM · BIOTECHNOLOGY

Insmed Incorporated (INSM) intrinsic value and stock valuation

$141.33as of 2026-11-21 · Mkt cap 21.46B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Insmed Incorporated DCF and intrinsic value

InvestorsCraft values INSM with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from INSM’s statements →

Insmed Incorporated Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bridgewater, NJ 08807 insmed.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$606.4M+29.8% 5y CAGRd
20112025
Net income
-$-1.28B
20112025
Free cash flow
-$-967.58M
20112025
Total equity
$739M+21.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$606.4M$363.7M$305.2M$245.4M$188.5M
Operating income-$-1.18B-$-878.25M-$-709.63M-$-457.32M-$-375.09M
Net income-$-1.28B-$-913.77M-$-749.57M-$-481.53M-$-434.65M
EPSd-$-5.98M-$-5.57M-$-5.34M-$-3.91M-$-3.88M
Operating cash flow-$-935.01M-$-683.88M-$-536.25M-$-400.44M-$-363.3M
Capital expenditure-$-32.56M-$-21.92M-$-13.29M-$-9.88M-$-7.29M
Free cash flow-$-967.58M-$-705.8M-$-549.53M-$-410.32M-$-370.59M
Total assets$2.26B$2.03B$1.33B$1.66B$1.24B
Total debt$768.2M$1.31B$1.2B$1.18B$612.3M
Net debt$257.7M$759.1M$721.6M$103.8M-$-104.51M
Total equity$739M$285.4M-$-331.92M$88M$410.5M
Cash and short-term investments$1.43B$1.43B$780.5M$1.15B$716.8M
Income statement
20252024202320222021
Revenue$606.4M$363.7M$305.2M$245.4M$188.5M
Cost of revenue$124.9M$85.7M$65.6M$55.1M$44.2M
Gross profit$481.6M$278M$239.6M$190.2M$144.3M
Research and development expenses$771.1M$598.4M$571M$397.5M$272.7M
Selling, general and administrative expenses$701.2M$461.1M$344.5M$265.8M$234.3M
Other expenses$186M$96.7M$33.8M-$-15.75M$12.4M
Operating expenses$1.66B$1.16B$949.3M$647.6M$519.4M
Cost and expenses$1.78B$1.24B$1.01B$702.7M$563.6M
Interest income$60.7M$53.3M$42.1M$11.1M$170K
Interest expense$83.8M$84.9M$81.7M$26.5M$40.5M
Depreciation and amortization$16.5M$11M$10.6M$10.3M$14.2M
Ebitda-$-1.17B-$-818.79M-$-660.18M-$-447.37M-$-383.65M
Operating income-$-1.18B-$-878.25M-$-709.63M-$-457.32M-$-375.09M
Total other income/expenses, net-$-95.02M-$-31.81M-$-37.39M-$-22.83M-$-61.32M
Income before tax-$-1.27B-$-910.07M-$-747.01M-$-480.15M-$-436.41M
Income tax expense$5.03M$3.71M$2.56M$1.38M-$-1.76M
Net income-$-1.28B-$-913.77M-$-749.57M-$-481.53M-$-434.65M
Weighted average shares outstanding$213.6M$164M$140.4M$123M$112.1M
Weighted average diluted shares outstanding$213.6M$164M$140.4M$123M$112.1M
Balance sheet
20252024202320222021
Cash and short-term investments$1.43B$1.43B$780.5M$1.15B$716.8M
Net receivables$140.9M$52M$41.2M$29.7M$24.4M
Inventory$132.1M$98.6M$83.3M$69.9M$67M
Total current assets$1.79B$1.62B$929.1M$1.27B$837M
Property, plant and equipment, net$139.2M$115.6M$104.4M$102.1M$95.5M
Goodwill and intangible assets$233.8M$194.8M$199.8M$204.9M$209.9M
Long-term investments$0.00$0.00$0.00$0.00$50M
Total non-current assets$470.4M$403.6M$400.8M$383.1M$406.5M
Total assets$2.26B$2.03B$1.33B$1.66B$1.24B
Accounts payable$79.9M$73M$65.4M$50.5M$35.8M
Short-term debt$19.3M$16.5M$10.6M$8.13M$10.1M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$468.9M$297.5M$225.6M$190.2M$135.2M
Long-term debt$748.9M$1.3B$1.19B$1.17B$602.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.06B$1.44B$1.44B$1.38B$697.9M
Capital lease obligations$32.9M$33.2M$48.7M$52.6M$45.7M
Total liabilities$1.53B$1.74B$1.66B$1.57B$833M
Common stock$2.14M$1.79M$1.48M$1.36M$1.19M
Retained earnings-$-5.64B-$-4.36B-$-3.45B-$-2.7B-$-2.27B
Accumulated other comprehensive income (loss)$1.46M-$-2.29M-$-740K$760K$970K
Total equity$739M$285.4M-$-331.92M$88M$410.5M
Total investments$919.6M$878.8M$298.1M$74.2M$50M
Total debt$768.2M$1.31B$1.2B$1.18B$612.3M
Net debt$257.7M$759.1M$721.6M$103.8M-$-104.51M
Cash flow statement
20252024202320222021
Net income-$-1.28B-$-913.77M-$-749.57M-$-481.53M-$-434.65M
Depreciation and amortization$16.5M$11M$10.6M$10.3M$14.2M
Stock-based compensation$152.7M$96.8M$74.8M$57.7M$46M
Change in working capital-$-80.3M-$-3.18M-$-39.22M$6.58M-$-58.58M
Accounts receivable-$-88.31M-$-12.93M-$-11.96M-$-6.42M-$-8.12M
Inventory-$-31.52M-$-17.04M-$-13.61M-$-1.71M-$-17.46M
Accounts payable$100.1M$44.6M$15.2M$50M-$-7.58M
Net cash provided by operating activities-$-935.01M-$-683.88M-$-536.25M-$-400.44M-$-363.3M
Investments in property, plant and equipment-$-32.56M-$-21.92M-$-13.29M-$-9.88M-$-7.29M
Acquisitions, net$0.00$0.00$3.42M$24.7M-$-6.7M
Net cash used for investing activities-$-64.58M-$-583.17M-$-223.6M-$-34.58M-$-64.28M
Common stock issued$959M$1.08B$152.5M$292.2M$269.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$954.1M$1.34B$168.4M$793.3M$612.6M
Net change in cash-$-44.59M$72.7M-$-591.66M$357.3M$184M
Cash at end of period$510.4M$555M$482.4M$1.07B$716.8M
Operating cash flow-$-935.01M-$-683.88M-$-536.25M-$-400.44M-$-363.3M
Capital expenditure-$-32.56M-$-21.92M-$-13.29M-$-9.88M-$-7.29M
Free cash flow-$-967.58M-$-705.8M-$-549.53M-$-410.32M-$-370.59M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Insmed Incorporated

        Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.

        CEO
        William H. Lewis
        Employees
        1.66K
        Beta
        0.78

        Explore

        Frequently asked questions

        What is the intrinsic value of Insmed Incorporated (INSM)?

        Insmed Incorporated (INSM) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is INSM undervalued?

        INSM trades at a price of $141.33 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.